685 related articles for article (PubMed ID: 24046014)
1. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
[TBL] [Abstract][Full Text] [Related]
2. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
3. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H
Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.
Inaba H; van Oosterwijk JG; Panetta JC; Li L; Buelow DR; Blachly JS; Shurtleff S; Pui CH; Ribeiro RC; Rubnitz JE; Pounds S; Baker SD
Clin Cancer Res; 2022 Jun; 28(12):2536-2546. PubMed ID: 35344039
[TBL] [Abstract][Full Text] [Related]
5. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
[TBL] [Abstract][Full Text] [Related]
6. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
[TBL] [Abstract][Full Text] [Related]
8. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.
Galanis A; Ma H; Rajkhowa T; Ramachandran A; Small D; Cortes J; Levis M
Blood; 2014 Jan; 123(1):94-100. PubMed ID: 24227820
[TBL] [Abstract][Full Text] [Related]
9. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
Ma HS; Greenblatt SM; Shirley CM; Duffield AS; Bruner JK; Li L; Nguyen B; Jung E; Aplan PD; Ghiaur G; Jones RJ; Small D
Blood; 2016 Jun; 127(23):2867-78. PubMed ID: 27103744
[TBL] [Abstract][Full Text] [Related]
10. Emergence of crenolanib for FLT3-mutant AML.
Fathi AT
Blood; 2013 Nov; 122(22):3547-8. PubMed ID: 24263951
[TBL] [Abstract][Full Text] [Related]
11. Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines.
Dayal N; Opoku-Temeng C; Hernandez DE; Sooreshjani MA; Carter-Cooper BA; Lapidus RG; Sintim HO
Future Med Chem; 2018 Apr; 10(7):823-835. PubMed ID: 29437468
[TBL] [Abstract][Full Text] [Related]
12. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
[TBL] [Abstract][Full Text] [Related]
13. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.
Man CH; Lam SS; Sun MK; Chow HC; Gill H; Kwong YL; Leung AY
Blood; 2014 Apr; 123(16):2530-9. PubMed ID: 24608976
[TBL] [Abstract][Full Text] [Related]
14. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S
Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205
[TBL] [Abstract][Full Text] [Related]
15. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
[TBL] [Abstract][Full Text] [Related]
16. Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
[TBL] [Abstract][Full Text] [Related]
17. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
[TBL] [Abstract][Full Text] [Related]
18. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with
Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H
Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
20. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
